Wedbush Boosts Earnings Estimates for Vigil Neuroscience

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Analysts at Wedbush boosted their FY2029 earnings per share estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, May 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.63 per share for the year, up from their prior estimate of $1.40. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share.

A number of other analysts have also recently weighed in on the stock. HC Wainwright decreased their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Finally, William Blair raised Vigil Neuroscience to a “strong-buy” rating in a report on Thursday, April 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.25.

Vigil Neuroscience Trading Up 0.4 %

Shares of Vigil Neuroscience stock opened at $2.42 on Friday. The firm has a market capitalization of $112.95 million, a PE ratio of -1.17 and a beta of 1.90. The firm’s 50 day moving average is $1.93 and its 200 day moving average is $2.31. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently modified their holdings of the business. 683 Capital Management LLC increased its holdings in Vigil Neuroscience by 14.8% in the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock valued at $2,380,000 after purchasing an additional 180,420 shares during the period. Blair William & Co. IL increased its stake in shares of Vigil Neuroscience by 219.1% in the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock valued at $1,840,000 after buying an additional 709,677 shares during the period. Ensign Peak Advisors Inc raised its position in shares of Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock worth $1,195,000 after acquiring an additional 97,580 shares during the last quarter. abrdn plc lifted its stake in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after acquiring an additional 293,461 shares during the period. Finally, Woodline Partners LP boosted its holdings in Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after acquiring an additional 344,614 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.